|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Epstein-Barr Virus(EBV) Panel
Test CodeEPBVP (Quest 77922)
Alias/See Also
Epstein-Barr Virus Ab Panel # 5 Quest #77922
Includes
Test Components 8426 Epstein-Barr VirusViralCapsid Antigen (VCA)AB(IgM) 8474 Epstein-Barr VirusViralCapsidAntigen (VCA)AB(IgG) 8564 Epstein-Barr Virus Nuclear Antigen (EBNA) AB (IgG) 15447 Epstein-Barr Virus, Early Antigen D Antibody (IgG)
Preferred Specimen
3.0 - 4.0 mL Serum (minimum 1.2 mL)
Instructions
Stability: Room Temperature: 4 days, Refrigerated: 7 days, Frozen: 30 days
Transport Container
SST or Red top Tube
Transport Temperature
Room Temperature
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross lipemia, gross hemolysis, or icterus.
Clinical Significance
Primary infection by EBV causes infectious mononucleosis, usually a self-limiting disease in children and young adults. Infection with EBV can cause lymphoproliferative disorders, including tumors. VCA-IgM typically appears approximately 4-6 weeks after initial infection and declines to undetectable in 1 month in young children and up to 3 months in others. VCA-IgG appears approximately 10 weeks after initial infection and persists for life. Absence of VCA-IgG typically indicates the patient is susceptible to infection. EBNA is detected during convalescence and high titers persist for life. VCA-IgM positivity in the absence of EBNA suggests the patient has a recent, active infection. Early Antigen D Antibody appears approximately 1 month after infection and typically is transient lasting only 1-2 months. Persistently elevated levels suggest reactivation or persistence of EBV infection. Early Antigen D Antibody appears approximately 1 month after infection and typically is transient lasting only 1-2 months. Persistently elevated levels suggest reactivation or persistence of EBV infection.
